pediatrics-neonatal-healthcare-2017-posters-abstracts

Page 44

Pediatrics & Neonatal Healthcare 2017

http://pediatrics.cmesociety.com

September 11-12, 2017 Los Angeles, CA, USA

World Pediatrics &

Neonatal Healthcare Conference

Journal of Pediatric Health Care and Medicine Volume 1, Issue 1

Notes:

Efficacy of current antibiotic regimens for neonatal sepsis at a tertiary hospital: Pathogens

and susceptibility, demographic profile, clinical manifestations and outcome, morbidity

and mortality rate

Anne Melva V Meliton

Makati Medical Center, Philippines

eonatal sepsis is a leading cause of morbidity and mortality among both term and preterm infants. With

growing antibiotic resistance, this retrospective, descriptive study determined if the current antibiotic

regimens used at a tertiary hospital are still effective against the pathogens identified in blood culture in cases

of neonatal sepsis from January 1, 2000 to December 31, 2015. Demographic profile, stratification to early- and

late-onset sepsis, clinical manifestations, laboratory results, complications and antimicrobial susceptibility of the

isolated organisms were analyzed. Prematurity and low birth weights were the major risk factors for developing

neonatal sepsis. Respiratory symptoms were the most common clinical manifestations seen. The pathogens were

evenly divided between gram-negative

bacilli

and gram-positive

cocci

, but gram-negative

bacilli

had higher

mortality rate. The current antibiotic regimen of cefuroxime and amikacin for early-onset neonatal sepsis were

changed in 57% of cases, indicating that a constant re-evaluation of any regimen is necessary to determine if an

antimicrobial upgrade is necessary. Although piperacillin-tazobactam has been favored for late-onset sepsis in the

unit in the last 15 years, more septic neonates ended treatment on a carbapenem. There was no growth of ESBL

E. coli

nor

Klebsiella pneumoniae

in blood isolates in spite of 15 years of current antimicrobial usage practices. A

regimen of cefuroxime and amikacin for early-onset sepsis will miss a minority of pathogens while a carbapenem

or piperacillin-tazobactam, with or without amikacin, is still effective for late-onset sepsis. Vancomycin, should

be added in late-onset sepsis, if staphylococcal disease is suspected.